Adjunctive Clindamycin Versus Linezolid for β-lactam Treated Patients With Invasive Group A Streptococcal Infections
Conditions: Streptococcal Sepsis; Invasive Group A Beta-Haemolytic Streptococcal Disease; Necrotizing Soft Tissue Infection; Infection, Bloodstream; Infection, Bacterial; Streptococcal Toxic Shock Syndrome Interventions: Drug: Linezolid; Drug: Clindamycin Sponsors: National Institutes of Health Clinical Center (CC); Emory University Active, not recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Clindamycin | Linezolid | National Institutes of Health (NIH) | Research | Toxic Shock Syndrome | Toxicology | Zyvox